Investor News
Investor News
Why Psyence?
Focused on natural psychedelics
Psyence is federally licensed to cultivate and export psilocybin mushrooms to the legal medical and research markets.
We have received import licenses from Health Canada and the Portuguese regulators for our psilocybin mushrooms.
Operational and revenue generating
Psyence is designing market-leading clinical trials in the field of palliative care. We have partnered with a leading psychedelic Contract Research Organisation (CRO) Clerkenwell Health, to design and deliver our first clinical trial in the UK.
Our ISO22000 state-of-the-art facility is fully operational and was recently expanded to enable us to meet future demand for our products.
Our non-psilocybin containing functional mushroom product, GOODMINDTM, is available online and in stores in South Africa.
Experienced scientific and medical team and capital markets expertise
Psyence CEO, Dr. Neil Maresky, is a physician and immediate past Vice President of Scientific Affairs at AstraZeneca Canada. Our scientific and medical team includes Dr. Clive Ward-Able, physician and pharma veteran with experience in therapeutic drug commercialization, Dr. Amza Ali, an internationally recognized neurologist, and Dr. Justin Grant, a leader in drug development.
Our capital markets team, Bayline Capital Partners, has a track record for creating shareholder value and achieving sustainable growth.
We have engaged UK Corporate Advisors, Hannam & Partners, to assist in exploring capital market opportunities in the UK and Europe in order access a broader pool of investors.
Why Psyence?
Focused on natural psychedelics
Psyence is federally licensed to cultivate and export psilocybin mushrooms to the legal medical and research markets.
We have received import licenses from Health Canada and the Portuguese regulators for our psilocybin mushrooms.
Operational and revenue generating
Psyence is designing market-leading clinical trials in the field of palliative care. We have partnered with a leading psychedelic Contract Research Organisation (CRO) Clerkenwell Health, to design and deliver our first clinical trial in the UK.
Our ISO22000 state-of-the-art facility is fully operational and was recently expanded to enable us to meet future demand for our products.
Our non-psilocybin containing functional mushroom product, GOODMINDTM, is available online and in stores in South Africa.
Experienced scientific and medical team and capital markets expertise
Psyence CEO, Dr. Neil Maresky, is a physician and immediate past Vice President of Scientific Affairs at AstraZeneca Canada. Our scientific and medical team includes Dr. Clive Ward-Able, physician and pharma veteran with experience in therapeutic drug commercialization, Dr. Amza Ali, an internationally recognized neurologist, and Dr. Justin Grant, a leader in drug development.
Our capital markets team, Bayline Capital Partners, has a track record for creating shareholder value and achieving sustainable growth.
We have engaged UK Corporate Advisors, Hannam & Partners, to assist in exploring capital market opportunities in the UK and Europe in order access a broader pool of investors.
Investor Sign-Up
Please enter your details below to receive investor updates on Psyence Group
